

July 27, 2018

To,

The Manager  
Listing Department  
National Stock Exchange of India Limited  
Exchange Plaza, 5th Floor  
Plot No. C1, 'G' Block, Bandra-Kurla Complex  
Bandra (East), Mumbai 400 051.

BSE Limited  
Corporate Relationship Department Floor  
25, P.J. Towers  
Dalal Street  
Mumbai 400 001.

**Symbol: RPGLIFE**

**Scrip code: 532983**

Dear Sirs,


**Sub: Press Release - Financial Results**

Please find enclosed herewith a copy of press release with respect to Unaudited Financial Results of the Company for the quarter ended June 30, 2018.

Kindly take the above on record.

Thanking you,

Yours faithfully,  
For RPG Life Sciences Limited

  
Rajesh Shirambekar  
Head - Legal & Company Secretary



Encl: As above



## RPG Life Sciences revenue from operations grows by 6.5 % and Substantial jump in Profit Before Tax Y-o-Y basis

**Mumbai, 27<sup>th</sup> July, 2018:** RPG Life Sciences Limited has announced its unaudited financial results for the quarter ended 30<sup>th</sup> June, 2018.

Q1 FY 19 Highlights	YoY Net Revenue from Operations (excluding excise duties)	YoY PBT from Operations
		Rs 79.89 crores – up from Rs 75.32 crores

RPG Life Sciences, engaged in the manufacturing and marketing of pharmaceutical products, posted a robust increase in revenue Y-O-Y for Q1 FY 19 at Rs. 79.89 crores which is a 6.5% increase as against Rs. 75.32 crores posted last year. The company's PBT stood at Rs 2.58 crores as against Rs.0.47 crores which marks a substantial jump.

“Despite the headwinds that the pharma industry is facing, we have demonstrated consistent performance in the last three years. Our YoY growth has been encouraging, notwithstanding the China influence on input price in the last two quarters. The nephrology, oncology and urology businesses are in line with our expectations, and the API business is doing exceptionally well. We have a robust order book and new products are showing promise. The blip in the QoQ performance is due to lower offtake of some of our products, however, secondary uptake is encouraging. We are optimistic of achieving growth in line with industry standards.”

Q1 FY19 Other Highlights	1. EDITDA margins improved from 6.1% to 8.7%
	2. Domestic formulation sales grew by 6%
	3. API net sales grew by 10%

**RPG Life Sciences Ltd ([www.rpglifesciences.com](http://www.rpglifesciences.com)):**

RPG Life Sciences Ltd, part of RPG Enterprises, is an integrated pharmaceutical company operating in the domestic and international markets in the branded formulations, global generics and synthetic APIs space. The company is a research-based pharmaceutical company, producing a wide range of quality, affordable medicines. Its brands are highly trusted by healthcare professionals and patients.

**RPG Enterprises ([www.rpggroup.com](http://www.rpggroup.com)):**

RPG Enterprises, established in 1979, is one of India's fastest growing business groups with a turnover of Rs 23000 Cr. The group has diverse business interests in the areas of Infrastructure, Tyres, Pharma, IT and Specialty as well as in emerging innovation-led technology businesses.

**Media Contact:**

**Sumeet Chatterjee**  
Senior Vice President – Group Communications  
RPG Group  
[sumeet@rpg.in](mailto:sumeet@rpg.in)  
+91 9820340650

